A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

May 20, 2026 updated by: Eli Lilly and Company

Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-20020 With BTKi Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

150

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
  • Phone Number: 1-317-615-4559
  • Email: LillyTrials@Lilly.com

Study Contact Backup

Study Locations

  • Australia
      • Liverpool, Australia, 2170
        • Not yet recruiting
        • Liverpool Hospital
        • Contact:
          • Phone Number: +61287385167
        • Principal Investigator:
          • Minh Hua
      • Melbourne, Australia, 3004
        • Not yet recruiting
        • The Alfred Hospital
        • Principal Investigator:
          • Constantine Tam
        • Contact:
          • Phone Number: 61396561111
  • Austria
      • Salzburg, Austria, 5020
        • Not yet recruiting
        • LKH - Universitätsklinikum der PMU Salzburg
        • Principal Investigator:
          • Alexander Egle
        • Contact:
          • Phone Number: +435725525822
  • Belgium
      • Roeselare, Belgium, 8800
        • Not yet recruiting
        • AZ Delta
        • Principal Investigator:
          • Lien Deleu
        • Contact:
          • Phone Number: +3251237322
  • Canada
      • Toronto, Canada, M5G 2M9
        • Not yet recruiting
        • Princess Margaret Cancer Centre - University Health Network
        • Contact:
          • Phone Number: 4169462827
        • Principal Investigator:
          • Christine Chen
  • China
      • Beijing, China, 100053
        • Not yet recruiting
        • Xuanwu Hospital Capital Medical University
        • Contact:
          • Phone Number: +8613691066953
        • Principal Investigator:
          • Wuhan Hui
      • Changsha, China, 410013
        • Not yet recruiting
        • Hunan Cancer Hospital
        • Principal Investigator:
          • Hui Zhou
      • Guangdong, China, 510060
        • Not yet recruiting
        • Sun yat-sen University Cancer Center
        • Principal Investigator:
          • He Huang
        • Contact:
          • Phone Number: +8613798032244
      • Guangzhou, China, 510515
        • Not yet recruiting
        • Nanfang Hospital of Southern Medical University
        • Principal Investigator:
          • RU FENG
        • Contact:
          • Phone Number: +8613725119762
      • Lanzhou, China, 730050
        • Not yet recruiting
        • Gansu Provincial Cancer Hospital
        • Principal Investigator:
          • Jie Cui
        • Contact:
          • Phone Number: +8613519607327
      • Nanchang, China, 330006
        • Not yet recruiting
        • The First Affiliated Hospital of Nanchang University
        • Principal Investigator:
          • Fei Li
        • Contact:
          • Phone Number: +86079188693682
      • Shanghai, China, 200032
        • Not yet recruiting
        • Fudan University Shanghai Cancer Center
        • Principal Investigator:
          • Junning Cao
      • Taizhou, China, 317000
        • Not yet recruiting
        • Taizhou Hospital of Zhejiang Province
        • Contact:
          • Phone Number: +8613515861286
        • Principal Investigator:
          • Qunyi Guo
      • Tianjin, China, 300060
        • Not yet recruiting
        • Tianjin Medical University Cancer Institute & Hospital
        • Contact:
          • Phone Number: +8618622221227
        • Principal Investigator:
          • Lihua Qiu
      • Tianjin, China, 300020
        • Not yet recruiting
        • Hematology Hospital of the Chinese Academy of Medical Sciences
        • Principal Investigator:
          • Rui Lv
        • Contact:
          • Phone Number: +8622023909015
      • Xuzhou, China, 221000
        • Not yet recruiting
        • The Affiliated Hospital of Xuzhou Medical College
        • Principal Investigator:
          • Jiang Cao
        • Contact:
          • Phone Number: +86516085802297
      • Zhengzhou, China, 450003
        • Not yet recruiting
        • Henan Cancer Hospital
        • Principal Investigator:
          • Keshu Zhou
        • Contact:
          • Phone Number: +864000371818
      • Ürümqi, China, 830000
        • Not yet recruiting
        • Affiliated Cancer Hospital of Xinjiang Medical University
        • Principal Investigator:
          • Shune Yang
        • Contact:
          • Phone Number: +869917968088
  • Croatia
      • Zagreb, Croatia, 10000
        • Not yet recruiting
        • University Hospital Center Zagreb
        • Contact:
          • Phone Number: +38512388675
        • Principal Investigator:
          • Igor Aurer
  • Czechia
      • Hradec Králové, Czechia, 500 05
        • Not yet recruiting
        • Fakultni nemocnice Hradec Kralove
        • Principal Investigator:
          • Martin Simkovic
        • Contact:
          • Phone Number: +420495834851
  • France
      • Rouen, France, 76038
        • Not yet recruiting
        • Centre Henri Becquerel
        • Contact:
          • Phone Number: +33232082223
        • Principal Investigator:
          • Stephane Lepretre
  • Hungary
      • Budapest, Hungary, 1097
        • Not yet recruiting
        • Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet
        • Principal Investigator:
          • Zoltan Matrai
        • Contact:
          • Phone Number: +3614558217
      • Debrecen, Hungary, 4032
        • Not yet recruiting
        • Debreceni Egyetem
        • Principal Investigator:
          • Illes Arpad
        • Contact:
          • Phone Number: +3652255196
  • Ireland
      • Dublin, Ireland, D08 NHY1
        • Not yet recruiting
        • St. James's Hospital
        • Principal Investigator:
          • Carmel Waldron
        • Contact:
          • Phone Number: +353868703651
      • Dublin, Ireland, DUBLIN 9
        • Not yet recruiting
        • Beaumont Hospital
        • Contact:
          • Phone Number: +35318092010
        • Principal Investigator:
          • Philip Murphy
  • Italy
      • Alessandria, Italy, 15121
        • Not yet recruiting
        • Azienda Ospedaliero - Universitaria Nazionale Santi Antonio e Biagio e Cesare Arrigo
        • Principal Investigator:
          • Gioacchino Catania
        • Contact:
          • Phone Number: +390131207825
      • Florence, Italy, 50134
        • Not yet recruiting
        • Azienda Ospedaliera Universitaria Careggi
        • Principal Investigator:
          • alessandro sanna
        • Contact:
          • Phone Number: +39557947958
      • Messina, Italy, 98158
        • Not yet recruiting
        • Presidio Ospedaliero Papardo
        • Contact:
          • Phone Number: +39903992246
        • Principal Investigator:
          • Donato Mannina
      • Monza, Italy, 20900
        • Not yet recruiting
        • Fondazione IRCCS San Gerardo dei Tintori
        • Principal Investigator:
          • Carlo Gambacorti-Passerini
        • Contact:
          • Phone Number: +390392331
      • Perugia, Italy, 06129
        • Not yet recruiting
        • Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia
        • Contact:
          • Phone Number: +39755783990
        • Principal Investigator:
          • PAOLO SPORTOLETTI
      • Rome, Italy, 00138
        • Not yet recruiting
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
        • Principal Investigator:
          • LUCA LAURENTI
        • Contact:
          • Phone Number: +390630156016
      • Tel Aviv, Italy, 6423906
        • Not yet recruiting
        • Tel Aviv Sourasky Medical Center
        • Principal Investigator:
          • Yair Herishanu
        • Contact:
          • Phone Number: 97236973576
      • Terni, Italy, 05100
        • Not yet recruiting
        • Azienda Ospedaliera S. Maria Di Terni
        • Principal Investigator:
          • Arcangelo Liso
        • Contact:
          • Phone Number: +39744205971
      • Verona, Italy, 37134
        • Not yet recruiting
        • Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma
        • Contact:
          • Phone Number: +393393847092
        • Principal Investigator:
          • Isacco Ferrarini
  • Japan
      • Isehara, Japan, 259-1193
        • Recruiting
        • Tokai University Hospital
        • Principal Investigator:
          • Yoshiaki Ogawa
        • Contact:
          • Phone Number: 81120023812
  • Poland
      • Brzozów, Poland, 36-200
        • Not yet recruiting
        • Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im.ks.B.Markiewicza
        • Contact:
          • Phone Number: +48134309728
        • Principal Investigator:
          • Jacek Krzanowski
      • Bydgoszcz, Poland, 85-168
        • Not yet recruiting
        • Szpital Uniwersytecki Nr 2 im. dr J. Biziela w Bydgoszczy
        • Principal Investigator:
          • Marta Sobas
        • Contact:
          • Phone Number: +48795149026
      • Katowice, Poland, 40-519
        • Not yet recruiting
        • Pratia Onkologia Katowice
        • Principal Investigator:
          • Sebastian Grosicki
        • Contact:
          • Phone Number: +48600388282
      • Warsaw, Poland, 02-776
        • Not yet recruiting
        • Instytut Hermatologii I Transfuzjologii
        • Principal Investigator:
          • Ewa Lech-Maranda
        • Contact:
          • Phone Number: +48223496334
  • Spain
      • Santander, Spain, 39008
        • Not yet recruiting
        • Hospital Universitario Marqués de Valdecilla
        • Contact:
          • Phone Number: +34942202520
        • Principal Investigator:
          • Lucrecia Yañez San Segundo
      • Seville, Spain, 41010
        • Not yet recruiting
        • Hospital Universitario Virgen del Rocio
        • Principal Investigator:
          • Fatima de la Cruz Vicente
        • Contact:
          • Phone Number: +34955013277
  • United Kingdom
      • Hull, United Kingdom, HU16 5JQ
        • Not yet recruiting
        • Castle Hill Hospital
        • Principal Investigator:
          • David Allsup
        • Contact:
          • Phone Number: +441482461296
      • Leeds, United Kingdom, LS9 7TF
        • Recruiting
        • St James's University Hospital
        • Principal Investigator:
          • Talha Munir
        • Contact:
          • Phone Number: +441132433144
      • Newmarket, United Kingdom, CB8 7XN
        • Not yet recruiting
        • GenesisCare
        • Principal Investigator:
          • George Follows
        • Contact:
          • Phone Number: +44 1223 816789
  • United States
    • Alabama
      • Mobile, Alabama, United States, 36693
        • Not yet recruiting
        • Mitchell Cancer Institute
        • Contact:
          • Phone Number: 334-660-5108
        • Principal Investigator:
          • Anita Mazloom
    • Arizona
      • Tucson, Arizona, United States, 85711
        • Not yet recruiting
        • Arizona Oncology Associates, P.C. - HOPE
        • Principal Investigator:
          • Sudhir Manda
        • Contact:
          • Phone Number: 520-886-0206
    • Florida
      • Jacksonville, Florida, United States, 32256
        • Not yet recruiting
        • Cancer Specialists, LLC
        • Contact:
          • Phone Number: 904-538-4488
        • Principal Investigator:
          • Ayed Ayed
    • Minnesota
      • Coon Rapids, Minnesota, United States, 55433
        • Not yet recruiting
        • Minnesota Oncology Hematology, P.A.
        • Contact:
          • Phone Number: 612-884-6300
        • Principal Investigator:
          • Avina Singh
    • New York
      • Ithaca, New York, United States, 14850
        • Not yet recruiting
        • Cayuga Cancer Center
        • Principal Investigator:
          • Cynthia Davis
      • New York, New York, United States, 10065-6007
        • Recruiting
        • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
        • Contact:
          • Phone Number: 646-608-4273
        • Principal Investigator:
          • Prioty Islam
    • Ohio
      • Cincinnati, Ohio, United States, 45211
        • Not yet recruiting
        • Oncology Hematology Care Inc
        • Contact:
          • Phone Number: 513-751-2273
        • Principal Investigator:
          • Kruti Patel
    • Texas
      • Fort Worth, Texas, United States, 76104
        • Not yet recruiting
        • Texas Oncology - Paris
        • Contact:
          • Phone Number: 214-370-1000
        • Principal Investigator:
          • Harris Naina
      • Kyle, Texas, United States, 78640
        • Not yet recruiting
        • US Oncology - Texas Oncology
        • Contact:
          • Phone Number: 210-595-5300
        • Principal Investigator:
          • David Friedman

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Are actively participating in study J2N-MC-JZNN/LOXO-BTK-20020

Exclusion Criteria:

  • This is not applicable to this study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Pirtobrutinib (Arm A)
Participants receive pirtobrutinib orally
Drug: Pirtobrutinib
Administered orally
Other Names:
  • LY3527727
Experimental: Idelalisib (Arm B)
Participants receive idelalisib orally
Drug: Idelalisib
Administered orally

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Percentage of Participants with a Grade 3 or Higher Treatment-emergent Adverse Events (AEs)
Time Frame: Time from First Dose of Study Intervention (Study Day 1) through 30 Days After Last Dose of Study Intervention or Start of New Anticancer Therapy, whichever is Earlier
Time from First Dose of Study Intervention (Study Day 1) through 30 Days After Last Dose of Study Intervention or Start of New Anticancer Therapy, whichever is Earlier

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall Survival
Time Frame: Time from Enrollment in the Originator Study until Death from Any Cause (Up to 93 Months)
Overall survival is defined as the time from randomization in a randomized originator study, or from the first dose in a non-randomized originator study, until death from any cause
Time from Enrollment in the Originator Study until Death from Any Cause (Up to 93 Months)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Eli Lilly and Company

Investigators

  • Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 9, 2026

Primary Completion (Estimated)

May 1, 2030

Study Completion (Estimated)

December 1, 2032

Study Registration Dates

First Submitted

October 16, 2025

First Submitted That Met QC Criteria

October 16, 2025

First Posted (Actual)

October 20, 2025

Study Record Updates

Last Update Posted (Actual)

May 22, 2026

Last Update Submitted That Met QC Criteria

May 20, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 27296
  • J2N-MC-JZNY (Other Identifier: Eli Lilly and Company)
  • J2N-MC-JZ03 (Other Identifier: Eli Lilly and Company)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement

IPD Sharing Time Frame

Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting

IPD Sharing Access Criteria

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Lymphocytic Leukemia

Clinical Trials on Pirtobrutinib

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe